The National Pharmaceutical Pricing Authority (NPPA) has announced new retail prices for 11 drug formulations, including cardiovascular, antibiotic, and anti-diabetic medications. These prices, excluding Goods and Services Tax (GST), are now legally binding. Manufacturers can only add GST if it's actually payable to the government, preventing inflated costs for consumers. Companies must issue price lists and display them prominently, with non-compliance leading to recovery of overcharged amounts plus interest.
The National Pharmaceutical Pricing Authority (NPPA) has notified the retail prices of 11 new drug formulations, acting under the powers granted by the Drugs (Prices Control) Order, 2013. The detailed order, published in the Gazette of India, specifies the retail prices (excluding GST) along with the drug strengths, units, and the names of manufacturers and marketing companies.
The notification, issued as S.O. 5476(E), applies to formulations submitted through Form-I for price fixation or revis
Daily Limit Reached
You have reached your daily limit of 2 Free News
Subscribe to
CCI PRO
for unlimited access
Why Upgrade to
CCI PRO?
-
No Ads
-
WhatsApp Community
-
Daily E-Newsletter
-
Unlimited News Access
-
Profile Visitors
-
Link Social Profiles
-
Featured Job Posts
-
Pro Badge
-
Expert GST Guidance
-
Unlimited Forum Replies
-
Download Content in PDF
1 Year PLAN
1999
(Excl. of GST ₹359)
BEST VALUE
2 Years PLAN
3499
(Excl. of GST ₹629)
3 Months PLAN
999
(Excl. of GST ₹179)
View all CCI PRO benefits
Already a PRO member?
Login here
for an ad-free experience.
FAQ :
The NPPA has notified the retail prices for 11 new drug formulations under the Drugs (Prices Control) Order, 2013.
The notification covers a range of drugs including cardiovascular, antibiotic, anti-allergic, anti-diabetic, and combination drugs.
Manufacturers may add GST only if it is actually payable to the government on the notified retail price, to avoid unjustified price inflation.
Manufacturers must issue a Form-V price list for all approved formulations from the date of notification and submit it to the NPPA, along with copies to State Drug Controllers and dealers.
If a manufacturer or marketer sells above the notified retail price, they will be required to deposit the overcharged amount with interest, and action will be taken under the DPCO 2013 and the Essential Commodities Act, 1955.
No, any previous price orders for these specific formulations, with the same strength and manufacturer/marketer, are superseded with immediate effect by this new notification.